Literature DB >> 10415721

Insights into MMP-TIMP interactions.

W Bode1, C Fernandez-Catalan, F Grams, F X Gomis-Rüth, H Nagase, H Tschesche, K Maskos.   

Abstract

The proteolytic activity of the matrix metalloproteinases (MMPs) involved in extracellular matrix degradation must be precisely regulated by their endogenous protein inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Disruption of this balance can result in serious diseases such as arthritis and tumor growth and metastasis. Knowledge of the tertiary structures of the proteins involved in such processes is crucial for understanding their functional properties and to interfere with associated dysfunctions. Within the last few years, several three-dimensional structures have been determined showing the domain organization, the polypeptide fold, and the main specificity determinants of the MMPs. Complexes of the catalytic MMP domains with various synthetic inhibitors enabled the structure-based design and improvement of high-affinity ligands, which might be elaborated into drugs. Very recently, structural information also became available for some TIMP structures and MMP-TIMP complexes, and these new data elucidated important structural features that govern the enzyme-inhibitor interaction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415721     DOI: 10.1111/j.1749-6632.1999.tb07675.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  42 in total

1.  Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease.

Authors:  H Gusman; J Travis; E J Helmerhorst; J Potempa; R F Troxler; F G Oppenheim
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

3.  Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles.

Authors:  Nathan S Trookman; Ronald L Rizer; Rosanne Ford; Elizabeth Ho; Vincent Gotz
Journal:  J Clin Aesthet Dermatol       Date:  2009-03

Review 4.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 5.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

6.  Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury.

Authors:  Carolina Moore; Xiu-Da Shen; Feng Gao; Ronald W Busuttil; Ana J Coito
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

7.  Matrix metalloproteinases (MMP-2 and MMP-9) activity in corneal ulcer and ocular surface disorders determined by gelatin zymography.

Authors:  Arti Singh; O P S Maurya; M V Jagannadhan; Ashok Patel
Journal:  J Ocul Biol Dis Infor       Date:  2012-12-29

Review 8.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

9.  Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts.

Authors:  Helen M Nugent; Robert Tjin Tham Sjin; Desmond White; Luther G Milton; Roberto J Manson; Jeffrey H Lawson; Elazer R Edelman
Journal:  J Vasc Surg       Date:  2007-09       Impact factor: 4.268

10.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Authors:  Lirong Peng; Xiaofang Xing; Weijun Li; Like Qu; Lin Meng; Shenyi Lian; Beihai Jiang; Jian Wu; Chengchao Shou
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.